Atria Investments Inc Makes New Investment in InMode Ltd. (NASDAQ:INMD)

Atria Investments Inc bought a new position in InMode Ltd. (NASDAQ:INMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,260 shares of the healthcare company’s stock, valued at approximately $208,000.

A number of other institutional investors have also modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in InMode by 11.6% during the second quarter. Renaissance Technologies LLC now owns 2,068,396 shares of the healthcare company’s stock worth $37,728,000 after purchasing an additional 214,200 shares during the last quarter. Doma Perpetual Capital Management LLC lifted its position in shares of InMode by 210.7% in the 2nd quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock worth $36,685,000 after buying an additional 1,363,841 shares during the last quarter. DDD Partners LLC boosted its holdings in shares of InMode by 19.4% in the 2nd quarter. DDD Partners LLC now owns 1,266,678 shares of the healthcare company’s stock valued at $23,104,000 after buying an additional 205,947 shares during the period. Federated Hermes Inc. grew its position in shares of InMode by 191.9% during the 2nd quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock valued at $20,520,000 after buying an additional 739,629 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in InMode by 63.6% during the second quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock worth $20,502,000 after acquiring an additional 437,122 shares during the period. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Trading Up 2.9 %

INMD opened at $19.02 on Friday. The business’s 50 day moving average is $17.40 and its 200-day moving average is $17.46. The stock has a market cap of $1.60 billion, a PE ratio of 10.28 and a beta of 2.15. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Barclays decreased their target price on InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research note on Monday, October 14th. Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Finally, BTIG Research began coverage on InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price on the stock. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $22.60.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.